New adaptive radiation boosts rectal cancer response rates

NCT ID NCT07580027

Not yet recruiting Disease control Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a personalized radiation approach for locally advanced rectal cancer. By adjusting the radiation dose halfway through treatment based on a special MRI scan, doctors hope to increase the number of patients whose tumors completely disappear before surgery. The trial will enroll 33 people to see if this method can raise the complete response rate from 41% to 70%.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (adaptive radiotherapy) and chemotherapy
What this could lead to: If successful, this approach could significantly increase the chance of eliminating the tumor before surgery, potentially reducing the need for more aggressive treatments.
What could go wrong: This is a small, early-phase study (33 participants) and the results may not apply to all patients. The treatment involves radiation and chemotherapy, which carry risks like fatigue, bowel issues, and skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal carcinoma rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED RECTAL CARCINOMA

Contacts and locations

Locations

I.R.C.C.S. San Raffaele Hospital

Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.